Ying Wang is the Chairman and President of Easton Biopharma, a pharmaceutical company that focuses on research and development (R&D), production, and sales of pharmaceutical products — from active pharmaceutical ingredients (APIs) to finished dosage forms (FDFs).
Over the years, Easton Biopharma has grown, owning five wholly funded subsidiaries. With an efficient and vigorous team of professionals, the company is committed to becoming a global pharmaceutical company for specific patented drugs.
While working as a good manufacturing practice (GMP) advisor, Ying realized that the management philosophy and management competence of domestic pharmaceutical companies were relatively lagging. And so, she came with an idea to start her own company where she could put her management philosophy and concepts into practice, and also drive pharmaceutical businesses to improve theirs — thus founding Easton Biopharma in 2009.
Ying holds an MBA from Guanghua School of Management, Peking University's business school. Prior to launching her company, Ying worked as a professional manager in a pharmaceutical company and as a GMP advisor at Beijing. Ying Wang, Chairman and President of Easton Biopharma, holds an EMBA from Guanghua School of Management, Peking University. She was a member of the 12th CPPCC of Sichuan Province, and selected as one of Science and Technology Innovation and Entrepreneurship Talents by the Ministry of Science and Technology, and listed in the National “Ten Thousand People Plan.”
Easton Biopharma was awarded many honorary titles, including the “National Intellectual Property Advantageous Enterprise”, “Outstanding Pharmaceutical Company for the 70th anniversary of the founding of New China”, and “Best Industrial Enterprise of China’s Pharmaceutical R&D Product Line." Also, Easton Biopharma was listed among “Top 100 Innovation Pharmaceutical Companies in China, “Top 20 Chinese Pharmaceutical R&D Companies,” “Top 50 Chinese Drug R&D Companies” and “Top 100 Chinese Pharmaceutical Companies.”